Circulating Mature Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Level Predicts Diminished Response to Statin Therapy in Patients With Coronary Artery Disease

被引：0
|
作者：
Naoto, Kuyama
Yu, Kataoka
Harada-Shiba, Mariko
Hori, Mika
Ogura, Masatsune
Asaumi, Yasuhide
Noguchi, Teruo
Yasuda, Satoshi
Kataoka, Yu
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A12784
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) is a Novel Risk Predictor in Statin-Treated Coronary Artery Disease Patients
    Werner, Christian
    Hoffmann, Michael M.
    Bohm, Michael
    Laufs, Ulrich
    CIRCULATION, 2014, 130
  • [2] Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
    Werner, Christian
    Hoffmann, Michael M.
    Winkler, Karl
    Boehm, Michael
    Laufs, Ulrich
    VASCULAR PHARMACOLOGY, 2014, 62 (02) : 94 - 102
  • [3] Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
    Kuyama, Naoto
    Kataoka, Yu
    Takegami, Misa
    Nishimura, Kunihiro
    Harada-Shiba, Mariko
    Hori, Mika
    Ogura, Masatsune
    Otsuka, Fumiyuki
    Asaumi, Yasuhide
    Noguchi, Teruo
    Tsujita, Kenichi
    Yasuda, Satoshi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (11):
  • [4] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [5] Circulating Levels of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) are Associated With Monocyte Subsets in Patients With Stable Coronary Artery Disease
    Krychtiuk, Konstantin
    Lenz, Max
    Hohensinner, Philipp
    Distelmaier, Klaus
    Schrutka, Lore
    Kastl, Stefan
    Pfaffenberger, Stefan
    Huber, Kurt
    Hengstenberg, Christian
    Wojta, Johann
    Speidl, Walter S.
    CIRCULATION, 2020, 142
  • [6] Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease
    Krychtiuk, Konstantin A.
    Lenz, Max
    Hohensinner, Philipp
    Distelmaier, Klaus
    Schrutka, Lore
    Kastl, Stefan P.
    Huber, Kurt
    Dostal, Elisabeth
    Oravec, Stanislav
    Hengstenberg, Christian
    Wojta, Johann
    Speidl, Walter S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (03) : 512 - 521
  • [7] Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease
    Hu, Die
    Yang, Yang
    Peng, Dao-quan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 61 - 65
  • [8] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) LEVEL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN RUSSIA
    Benimetskaya, Kseniya
    Ragino, Yulia
    Shakhtshneider, Elena
    Makarenkova, Kseniya
    Stakhneva, Ekaterina
    Astrakov, Sergey
    Shchepina, Yulia
    Voevoda, Mikhail
    ATHEROSCLEROSIS, 2017, 263 : E195 - E195
  • [9] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [10] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
12345